Abstract
BackgroundTumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.MethodsWe analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019, in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.ResultsIn the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR = 2.72, 95% CI = 1.95–3.8, P < 0.00001), high tumor stage (OR = 3.94, 95% CI = 2.80–5.53, P < 0.00001), high grade (OR = 2.04, 95% CI = 1.18–3.51, P = 0.01), distant metastasis (OR = 2.20, 95% CI = 1.40–3.46, P = 0.0006), tumor size (OR = 2.79, 95% CI = 1.89–4.14, P < 0.00001), and lymph node metastasis (OR = 2.66, 95% CI = 1.65–4.29, P < 0.0001).ConclusionsOur study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.
Highlights
Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases
In the tumor samples of the The Cancer Genome Atlas (TCGA) database, the Small nucleolar RNA host gene 12 (SNHG12) expression level was low in glioma, Breast invasive carcinoma (BRCA), Acute Myeloid Leukemia (LAML), LUAD, Lung squamous cell carcinoma (LUSC), and KICH and high in DLBG, Head and Neck squamous cell carcinoma (HNSC), KIRC, and THYM (Fig. 1A)
All of the patients in the 10 studies were from Asia and had 9 types of tumors, including nasopharyngeal carcinoma (NPC), colorectal cancer (CRC), cervical cancer (CVC), breast cancer (BC), gastric cancer (GC), hepatocellular cancer (HCC), non-small cell lung carcinoma (NSCLC), osteosarcoma, and glioma (Supplementary Table S1)
Summary
Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. It was gradually recognized that lncRNAs are involved in transcriptional and post-transcriptional regulation by recruiting transcription factors, remodeling chromatin, splicing premRNA, and acting as molecular sponges and scaffolds in multifarious diseases and tumors. These molecules act as tumor promoters or tumor suppressors in the multistep development of human tumors [5, 6, 7]. LncRNAs can be present in many tissues and fluids for a long time, and can be used as a biomarker for extensive screening of diseases [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
